Company information
Neoventa Medical AB is a medtech company developing monitoring and management tools for improved perinatal healthcare. The company is based in Mölndal close to Göteborg in Sweden. Neoventa has combined a unique medical expertise with digital signal processing technology to establish ST analysis of the fetal heart as one of the most exciting advances within the field of perinatal medicine. STAN™ S31 is the latest of a series of products for this purpose.
Formation and ownership
Neoventa Medical AB was founded in mid 1997. The company is a Swedish limited company based in Mölndal.
The major investors in Neoventa Medical AB are Investor Growth Capital AB, CapMan Life Science, SEB Företagsinvest and the company staff.
Board of directors
Thomas Axelsson, MSc, Chairman of the Board.
Björn Österlund, BSc, is Senior Investment Manager at SEB Företagsinvest.
Thomas Eklund, General Manager, Investor Growth Capital AB.
Johan Bennarsten, MD MSc, Investment Director at CapMan Life Science.
Seppo Luode, MBA MSc
Dan Pitulia, CEO of Carmel Pharma
Deputy Members
Viktor Drvota, MD PhD, Ass. Prof (Cardiology) Business Development, Life Science SEB Venture Capital.
Jakob Lindberg, Vice President, Investor Growth Capital AB.
Björn Nordenvall, PhD MD, Investment Director, CapMan Life Science.
Management
Jan Stålemark, CEO
Arne Samuelsson, Technical Director
Elisabet Lund, CFO
Lena Hagman, Operation Director
Maria Granberg, Marketing Director
Håkan Skytt, Sales Director
Quality assurance and Regulatory Affairs
Neoventa is certified under ISO 13485:2003. Downloadable certificates are available here.
About this website
If you have questions regarding this website, please send an e-mail to info@neoventa.com.
Cookies are not used on this website.
STAN™, Goldtrace™ and the STAN baby logo are trademarks of Neoventa Medical AB.